➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
McKesson
Johnson and Johnson
Harvard Business School
Mallinckrodt

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Patent: 9,375,496

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,375,496
Title:Halogenated compounds for cancer imaging and treatment and methods for their use
Abstract: Compounds having a structure of Formula I: ##STR00001## or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or .sup.123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.
Inventor(s): Andersen; Raymond John (Vancouver, CA), Banuelos; Carmen Adriana (Richmond, CA), Garcia Fernandez; Javier (Colunga, ES), Imamura; Yusuke (Chiba, JP), Kunzhong; Jian (Vancouver, CA), Mawji; Nasrin R. (Burnaby, CA), Sadar; Marianne Dorothy (West Vancouver, CA), Wang; Jun (Surrey, CA), Tien; Amy (Hsing Chen) (Vancouver, CA)
Assignee: British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA)
Application Number:14/481,727
Patent Claims:see list of patent claims

Details for Patent 9,375,496

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Start Trial British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA) 2033-09-09 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA) 2033-09-09 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA) 2033-09-09 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Mallinckrodt
McKinsey
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.